Monopar Therapeutics (MNPR) Equity Average (2018 - 2025)

Monopar Therapeutics has disclosed Equity Average across 8 years of filings, most recently posting $139.7 million for Q4 2025.

• Equity Average for Q4 2025 came in at $139.7 million, up 365.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $139.7 million (up 365.77% YoY), and the FY2025 annual result was $96.4 million, up 218.13% from the prior year.
• Equity Average came in at $139.7 million for Q4 2025 at Monopar Therapeutics, up from $96.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $139.7 million in Q4 2025 to a low of $5.5 million in Q3 2024.
• The 5-year median for Equity Average is $16.8 million (2022), against an average of $28.5 million.
• Across the five-year window, Equity Average plunged 46.99% in 2023 and jumped 1655.53% in 2025, its largest moves.
• Monopar Therapeutics' Equity Average stood at $20.1 million in 2021, then plunged by 43.81% to $11.3 million in 2022, then tumbled by 46.02% to $6.1 million in 2023, then jumped by 391.7% to $30.0 million in 2024, then soared by 365.77% to $139.7 million in 2025.
• The last three Equity Average figures came in at $139.7 million (Q4 2025), $96.9 million (Q3 2025), and $52.9 million (Q2 2025), per Business Quant data.